The Reagent Drawer Is Not an Archive: Why Antibody Knowledge Needs a Succession Plan
Antibody laboratories are good at generating knowledge and poor at keeping it. A postdoc may spend eighteen months characterising a new clone, establishing the working dilution for immunohistochemistry, testing cross-reactivity, and learning which lot of secondary antibody behaves badly in a particular tissue. When the contract ends, that knowledge often leaves in a personal notebook, a laptop folder or, worse, a memory.
This is not a failure of individual diligence. It is a structural problem. UK life-science research runs on fixed-term contracts, grant cycles and project-specific appointments. The same rhythm that brings fresh expertise into a lab also removes it. The antibody reagents remain in the freezer, but the context that made them useful does not.
The invisible evidence
Validation data are usually recorded somewhere. The problem is that somewhere is rarely designed for the next person. An image may show clean staining, but the protocol that produced it may be in a colleague's email. A lot history may be noted in a spreadsheet, but the reason a particular lot was retired may exist only as a caution passed on at the bench. Troubleshooting wisdom is especially vulnerable: the knowledge that a certain antibody needs an overnight incubation, or that a particular blocking buffer reduces background in mouse tissue, is often treated as informal craft rather than data.
The result is a quiet form of waste. New researchers repeat optimisation work. Core facilities answer the same questions. Procurement teams re-order reagents that were already validated but never recorded in a shared system. In the worst cases, a diagnostic assay drifts because the institutional memory of how it was originally verified has gone.
A registry is not a database project
The solution is not necessarily a new enterprise platform. Many laboratories would benefit from a modest, shared antibody registry that sits alongside existing records. The essential fields are not exotic: target, clone, host species, vendor, catalogue number, lot number, concentration, storage conditions, validated applications, sample types, positive and negative controls, and the date of the last verification. Research Resource Identifiers, or RRIDs, are useful where they exist, because they give a stable citation for a reagent.
The more important field is the narrative one. What did this antibody fail to do? Which lot was problematic? Which protocol version was used? A registry that records only the successes is a catalogue, not a memory. A short free-text note can be more valuable than a pristine table if it explains why a reagent was abandoned or why a particular dilution became the lab standard.
Habits that survive turnover
Documentation habits do not need to be heavy to be effective. A ten-minute handover note at the end of a contract is better than a perfect system that nobody maintains. A one-page antibody passport for each routinely used reagent can travel with the vial and the electronic record. A version-controlled standard operating procedure for the assay, with a change log, gives the next researcher a starting point rather than a mystery.
There is also a cultural point. Laboratory culture tends to reward the experiment, not the record. The result is that documentation is left to the end of a project, when time is short and attention is elsewhere. A more sustainable approach is to make recording part of the experiment itself: capture the lot number when the assay is run, note the control performance at the time, and file the image with the protocol version. These are small acts, but they accumulate into institutional memory.
Shared registries also change behaviour. When a new researcher can see that a reagent has been validated for a specific application by a predecessor, they are less likely to repeat work and more likely to trust the record. When they can see that a lot was retired for a reason, they are less likely to repeat the failure.
The cost of forgetting
UK laboratories face pressure on space, funding and time. Antibody reagents are expensive, but the knowledge attached to them is often more valuable than the vial itself. A validated antibody with a clear lot history and a documented protocol is an asset. The same antibody without that context is a guess.
The argument, then, is not for bureaucracy. It is for a lightweight discipline that recognises antibody knowledge as a laboratory asset. The next postdoc will leave too. The question is whether the data leave with them, or whether the laboratory has built a way to keep it. In a field where reproducibility is a persistent concern, that is not an administrative detail. It is part of the science.
